Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 5/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411362 | 0.84 | ALDH1A1 (0.58) | MAPTPPARGNCOA1NPSR1NCOA3 | |
| SCHEMBL15960099 | 0.83 | GSK3B (0.39) | MAPTKMT2ANPSR1KDM4EPOLB | |
| SCHEMBL15962456 | 0.83 | ALOX15 (0.47) | MAPTHSD17B10KMT2APPARGNPSR1 | |
| SCHEMBL669321 | 0.83 | RAF1 (0.39) | MAPTHSD17B10TSHRKMT2APPARG | |
| SCHEMBL1406076 | 0.83 | MAPT (0.47) | MAPTPPARGNCOA1NPSR1NCOA3 | |
| SCHEMBL613592 | 0.83 | KDM4E (0.40) | MAPTHSD17B10TSHRKMT2APPARG | |
| SCHEMBL612154 | 0.81 | IKBKB (0.53) | KDM4EALDH1A1MAPK14GSK3BACHE | |
| SCHEMBL319034 | 0.81 | GSK3B (0.53) | MAPTHSD17B10TSHRKMT2APPARG | |
| SCHEMBL11888070 | 0.79 | MAPT (0.44) | MAPTHSD17B10TSHRKMT2AKDM4E | |
| SCHEMBL2730725 | 0.79 | MAPT (0.44) | MAPTHSD17B10TSHRKMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158693-A1 | Probe for Hydrogen Sulfide Detection, Method for Manufacturing Same, and Composition for Hydrogen Sulfide Detection, Comprising Same | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2024-05-16 | — | — | US | disclosed |
| WO-2022131557-A1 | PROBE FOR HYDROGEN SULFIDE DETECTION, METHOD FOR MANUFACTURING SAME, AND COMPOSITION FOR HYDROGEN SULFIDE DETECTION, COMPRISING SAME | 한국해양과학기술원 | 2022-06-23 | — | — | WO | disclosed |
| US-11306103-B2 | Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY | 2022-04-19 | — | — | US | disclosed |
| US-11306103-B2 | Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY | 2022-04-19 | — | — | US | disclosed |
| US-20210171539-A1 | NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2021-06-10 | — | — | US | disclosed |
| US-20210171539-A1 | NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2021-06-10 | — | — | US | disclosed |
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
| EP-2150251-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | EGLN3, HIF1AN, EGLN2 | MAPT 4145/4885HSD17B10 445/4885TSHR 3671/4885 |
| US-20210171539-A1 | NOVEL THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | BRD4, BRPF3, AFF4 | MAPT 2916/4885HSD17B10 1772/4885TSHR 1211/4885 |
| US-11306103-B2 | Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof | BRD4, BRPF3, AFF4 | MAPT 2983/4885HSD17B10 1574/4885TSHR 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.